Abbott and Piramal - Top 5 Emerging Market Deals

Who: Abbott Laboratories
With:
Piramal
Where:
India

Deal size: $3.7 billion

Details: Big drugmakers like Sanofi-Aventis and Pfizer expressed interest, but it was Abbott that captured the domestic unit of India's Piramal Healthcare. Abbott paid $2.12 billion up front and will make payments of $400 million annually for the next four years, beginning in 2011.

India is one of the world's fastest-growing pharmaceutical markets. Pharma sales are expected to hit $8 billion in 2010 and double by 2015. With the purchase, Abbott captures about seven percent of India drug market and gives it the industry's largest sales force in that country. It expects revenues there to grow by about 20 percent a year to more than $2.5 billion by 2020.

Abbott and Piramal - Top 5 Emerging Market Deals
Read more on

Suggested Articles

One year after its landmark Reduce-It CV outcomes trial, Amarin has new data showing its Vascepa may help halt the progress of arterial plaque.

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.